Sanofi/Regeneron's Asthma Candidate Meets Goal In Study
Zacks Investment Research | Jun 20, 2019 10:30PM ET
Sanofi (PA:SASY) (NASDAQ:SNY) and partner Regeneron Pharmaceuticals, Inc, (NASDAQ:REGN) announced that a phase II study evaluating their investigational IL-33 antibody REGN3500 (SAR440340) in asthma met the primary endpoint.
Top-line data from the phase II proof-of-concept study on the candidate showed that REGN3500 (SAR440340) monotherapy significantly reduced loss of asthma control (primary endpoint) and improved lung function (secondary endpoint) compared to placebo.
The study had four treatment groups namely REGN3500 plus placebo, REGN3500 plus Dupixent, Dupixent plus placebo, and placebo. Dupixent is Sanofi/Regeneron’s successful new drug, which is marketed for atopic dermatitis as well as moderate-to-severe asthma.
Coming back to the phase II REGN3500 study, patients in the Dupixent monotherapy group did numerically better than REGN3500 across all endpoints. Interestingly, the REGN3500 plus Dupixent group failed to demonstrate increased benefit compared to Dupixent monotherapy. The percentage of adverse events was 61.6% in the REGN3500 patient group, 66.2% in the REGN3500 and Dupixent group, 56.8% in Dupixent and 64.9% in the placebo patient group.
Sanofi and Regeneron are developing REGN3500 in phase II studies for atopic dermatitis, asthma and chronic obstructive pulmonary disease (COPD).
Sanofi’s stock has risen 1.2% this year so far, underperforming the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.